180 Life Sciences Teams Up With Hadassah Hospital To Test A New Formulation Of CBD For Enhanced Oral Uptake

180 Life Sciences Corp. ATNF has reached an agreement with professor Avi Domb of the Hebrew University, School of Pharmacy, and with professor Elyad Davidson, of Hadassah Hospital, to perform a clinical pharmacology (“pharmacokinetic” or “PK”) study of the uptake of CBD in a formulation which can be delivered as a pill orally. The PK study will seek to determine how much CBD is taken up into the blood of volunteers.

While CBD preparations have previously been approved by the U.S. Food and Drug Administration for rare forms of childhood epilepsy, a major problem in working with CBD is its low and unpredictable and variable uptake following the most convenient delivery form, by mouth, as CBD in oil. This has hampered progress and clinical trials seeking potential uses for CBD, such as for the treatment of pain, post-traumatic stress disorder (PTSD), head trauma, and more, where reports have suggested the possibility of benefits.

To help try to solve this problem, Domb and colleagues have developed “ProNanoLipospheres”, a mixture of components available over-the-counter, which form little droplets and have been shown to be absorbed from the gastrointestinal tract into blood. The dosage form has been shown in preliminary testing in rats to increase uptake of CBD, decrease absorption variability and enable controlled release pharmacokinetics. Based on these animal results, a human PK study is being designed to test whether the formulation increases CBD blood levels after oral administration. This PK study will be performed at Hadassah Hospital executed by an experienced team under the supervision of Davidson and Domb, in collaboration with 180 Life Sciences.

”We are delighted to collaborate with the team at 180 Life Sciences, including professor Marc Feldmann, who pioneered the development of anti-tumor necrosis factor antibodies for rheumatoid arthritis,” stated Domb. “Ultimately, our team’s formulation may use pure synthetic CBD, which we believe in many countries is not subject to controlled substance regulations, but in other countries may be subject to local regulations, and which we believe will be convenient to administer”, added Domb.

Price Action

180 Life Sciences shares were trading 12.07% higher at $0.919 per share at the time of writing Monday morning.

Benzinga Cannabis Capital Conference

The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.

Photo by Louis Reed on Unsplash

Related News

180 Life Sciences Files A Provisional Patent For CBD-Based Appetite Suppressant